Clinical Trial Search

Primary: Amount of Nicotine (mL of Smoke/Vapor) Inhaled — 0; 489.0; 1814.0; 1401.0 Volume in mL

Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…

Primary: Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 5.1; 67.2; 66.1 score on a scale

Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants

Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio

Primary: Tolerability — 0; 0; 0 Participants

Primary: Mean Peak Change From Baseline Anxiety as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 13.8; 18.7; -1.9 score on a scale

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Cannabis Self-administration — 5.75; 9.2; 5.75; 7.5 puffs of cannabis chosen

Primary: Marijuana Use — 2.5; 3.9 Reported uses per day

Primary: Mood Scale - Subscale 'Feeling High' — 4.35; 2.48; 0.39; 6.55 units on a scale VAS 1-100 mm

Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars

Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…

Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams

Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants

Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score

Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale

Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day

Primary: Brain Reward Circuit Activation on fMRI Scan — 0.05; 0.14; 0.18; 0.12 z-score — p=0.87

Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — 198.3; 55.9 ng/mg

Primary: Validity of the Marijuana Purchase Task (MPT) — 63 percentage of participants — p=.00000004

Primary: Cannabis Approach Bias — -8.43; 4.05; 5.43; -1.36 seconds

Primary: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. — 18; 17 participants

Primary: Alpha Learning Rate — .62; .43; .55; .21 Alpha Coefficient

Primary: Change in Marijuana Withdrawal Checklist (MWC) — 6.04; 11 score on a scale

Primary: Alcohol Craving — 2.54; 2.64; 2.65; 2.55 units on a scale

Primary: Cannabis Use — 55.89; 63.10 Percentage of use days

Primary: Change From Baseline in Profile of Mood States (POMS) — 2.58; 4.28; 8.25; 0.7 units on a scale

Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 7.2; 6.4 percentage of UDS